Pyrazolo pyrimidine derivatives and their use as MALT1 inhibitors

US9815842B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Carole Pissot Soldermann · Basel, CH
• Jean Quancard · Huningue, FR
• Achim Schlapbach · Bad Kötzting, DE
• Oliver Simic · Basel, CH
• Marina Tintelnot-Blomley · Maulburg, DE
• Thomas Zoller · Andolsheim, FR

Key dates

• Filing date: May 27, 2015
• Grant date: Nov 14, 2017
• Expiry date: May 27, 2035

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention describes new pyrazolo-pyrimidine derivatives which are generally interacting with MALT1 proteolytic and/or autoproteolytic activity, and in particular which may inhibit said activity. The present invention further describes the synthesis of said new pyrazolo-pyrimidine derivatives, their use as a medicament, especially by interacting with MALT1 proteolytic and/or autoproteolytic activity.